Trust and accountability
Cliniva China Editorial Standards
These public policies explain how Cliniva creates, reviews, corrects, updates, measures, and safeguards health information and original research.
Ten public policies
How our content standards work
Each policy states an operational rule readers can use to understand or challenge Cliniva's work. The Privacy Notice and Terms remain separate legal pages and are linked where they apply.
- Cliniva China Editorial Policy
This policy explains who chooses topics, how evidence is used, and how editorial work remains distinct from patient coordination.
- Cliniva China Medical Review Policy
Medical review checks the clinical accuracy, balance, limitations, and source fit of a specific content revision before publication.
- Cliniva China Sources Policy
Sources are selected according to the claim being made, with clinical evidence kept separate from hospital-provided service information.
- Cliniva China Corrections Policy
Readers can report errors through Cliniva's contact channel, and clinically meaningful corrections are reviewed and visibly dated.
- Cliniva China Content Updates Policy
Medical content has a six-month review target and may be reviewed sooner when evidence, guidance, or safety information changes.
- Cliniva China Conflicts of Interest Policy
Cliniva coordinates enquiries with hospitals, but partner relationships do not create guaranteed placement, outcomes, or favorable editorial treatment.
- Cliniva China Data Methodology
Original tables and comparisons must be reproducible from a defined scope, dated inputs, explained calculations, and visible limitations.
- Cliniva China Patient Safety Policy
Cliniva content and Case Review coordination are not emergency services and do not replace diagnosis or treatment decisions from a clinician.
- Cliniva China Analytics Privacy Standard
Site measurement is designed for aggregate performance reporting without collecting medical details, form values, or case references.
- Cliniva China Research Ethics Policy
Original research and patient-related material require proportionate review, explicit authorization, and safeguards against identification or fabrication.